Drugs Containing Excipient (Inactive Ingredient) POLYOXYL 60 HYDROGENATED CASTOR OIL

Generic drugs containing POLYOXYL 60 HYDROGENATED CASTOR OIL excipient

Company	Ingredient	NDC	Excipient
Amneal Pharmaceuticals of New York LLC	lidocaine and prilocaine	0115-1468	POLYOXYL 60 HYDROGENATED CASTOR OIL

Polyoxyl 60 Hydrogenated Castor Oil Market Dynamics and Financial Trajectory

Last updated: August 28, 2026

Polyoxyl 60 hydrogenated castor oil is a nonionic surfactant and pharmaceutical excipient used primarily as a solubilizer, emulsifier, wetting agent, and viscosity-modifying aid. The market is driven by formulation demand rather than direct pharmaceutical consumption because the material is rarely sold as a branded finished medicine or reported as a standalone market segment.

Public financial data for polyoxyl 60 hydrogenated castor oil is limited. Manufacturers generally report it within broader pharmaceutical excipient, surfactant, or specialty ingredients divisions. The strongest commercial indicators are formulation-development activity, supplier qualification, regulatory acceptance, demand for poorly water-soluble drugs, and the expansion of oral, topical, and selected parenteral dosage forms.

What is polyoxyl 60 hydrogenated castor oil?

Polyoxyl 60 hydrogenated castor oil is a polyethylene glycol derivative of hydrogenated castor oil. It is also identified by related names including PEG-60 hydrogenated castor oil, hydrogenated castor oil macrogolglycerol, and macrogolglycerol hydroxystearate 60, depending on the applicable compendial or regulatory nomenclature.

Attribute	Description
Chemical class	Nonionic polyoxyethylene surfactant
Primary function	Solubilizer, emulsifier, wetting agent
Common identifier	PEG-60 hydrogenated castor oil
CAS reference commonly associated with the material	61788-85-0
Physical form	Waxy solid, flakes, pellets, or granules depending on supplier
Typical formulation role	Solubilization of lipophilic active ingredients and stabilization of emulsions
Relevant dosage forms	Oral liquids, suspensions, emulsions, topical products, selected injectable formulations
Regulatory category	Inactive pharmaceutical ingredient or excipient
Main commercial risk	Supply qualification and formulation substitution risk rather than active-ingredient patent risk

The number “60” generally refers to the approximate polyethylene oxide content or degree of ethoxylation used to characterize the grade. Commercial specifications can differ in hydroxyl value, saponification value, acid value, water content, ethylene oxide distribution, and impurity profile.

Polyoxyl 60 hydrogenated castor oil should not be treated as interchangeable with all related castor-oil surfactants. Polyoxyl 35 castor oil, PEG-40 hydrogenated castor oil, and macrogol 15 hydroxystearate have different composition profiles and may produce different solubilization, viscosity, osmolality, extractables, and tolerability outcomes.

What are the main pharmaceutical applications of polyoxyl 60 hydrogenated castor oil?

The principal application is the solubilization and stabilization of poorly water-soluble active pharmaceutical ingredients. The excipient can reduce interfacial tension, improve wetting, and support the formation of emulsions or micellar systems.

Oral formulations

Oral liquids and suspensions are important application areas because many drug substances have low aqueous solubility. Polyoxyl 60 hydrogenated castor oil can help maintain a uniform dispersion and reduce precipitation after dilution or storage.

Potential formulation uses include:

• Oral solutions and concentrates
• Suspensions
• Emulsions
• Soft-gel and lipid-based systems
• Pediatric liquid formulations
• Nutraceutical and over-the-counter products

Its use must be evaluated against taste, gastrointestinal tolerability, peroxide formation, preservative compatibility, and the risk of altered drug absorption.

Topical and dermatological formulations

The material can support emulsification and dispersion in creams, lotions, gels, and other semisolid products. Demand in this segment follows the development of poorly soluble dermatological actives and consumer products that require stable oil-in-water systems.

Parenteral products

Hydrogenated castor-oil-derived surfactants have been used in solubilizing systems for injectable products, but parenteral applications face a higher regulatory and safety burden. Requirements include control of endotoxin, bioburden, particulate matter, residual ethylene oxide-related impurities, oxidative degradation, and container-closure compatibility.

A grade accepted for oral use is not automatically suitable for injection. The drug manufacturer must qualify the exact supplier, grade, manufacturing site, specifications, and sterilization or bioburden-control process.

How large is the polyoxyl 60 hydrogenated castor oil market?

No reliable public source reports a standalone global revenue figure for polyoxyl 60 hydrogenated castor oil. Supplier disclosures normally aggregate the product into broader categories such as pharmaceutical excipients, solubilizers, surfactants, or specialty chemicals.

The addressable market is best analyzed through four layers:

Market layer	Commercial relevance	Data visibility
Polyoxyl 60 hydrogenated castor oil	Direct product sales	Low
Pharmaceutical solubilizers and surfactants	Closest functional market	Moderate
Specialty pharmaceutical excipients	Broader supplier category	Moderate to high
Formulation services for poorly soluble drugs	Demand-generation layer	Moderate

The product is a niche excipient rather than a high-volume commodity comparable with lactose, microcrystalline cellulose, starch, or polyethylene glycol. Its value per kilogram can be higher than basic excipients because pharmaceutical customers pay for documentation, batch consistency, regulatory support, supply continuity, and validated manufacturing controls.

The market is therefore characterized by modest physical volumes, high qualification costs, and relatively sticky customer relationships after approval.

What is driving demand for polyoxyl 60 hydrogenated castor oil?

Poor aqueous solubility of new drug candidates

Low solubility remains a central formulation problem, particularly for small molecules discovered through lipophilic and targeted medicinal chemistry programs. Surfactants such as polyoxyl 60 hydrogenated castor oil can be considered during preformulation and early clinical development.

Growth in oral liquid development

Oral liquids require excipients that can solubilize or suspend the active ingredient while meeting taste, stability, dose-uniformity, and pediatric-use requirements. The expansion of pediatric medicines and reformulated products supports demand for nonionic surfactants.

Lifecycle management

Established drugs may be reformulated into liquids, dispersible products, improved bioavailability systems, or combination products. These programs can create excipient demand even when the active ingredient is off patent.

Outsourced formulation development

Contract development and manufacturing organizations increasingly select excipients during early development. Once a formulation is transferred into clinical or commercial production, replacement of a qualified excipient can require comparability work, stability studies, and regulatory review.

Regulatory preference for established excipients

A material with compendial recognition, prior pharmaceutical use, and documented toxicology generally has an advantage over a new surfactant. FDA’s Inactive Ingredient Database provides an important reference point for prior use by route and dosage form, although database presence does not constitute blanket approval for every formulation or dose.[1]

What factors could limit market growth?

Polyoxyl 60 hydrogenated castor oil competes with several excipient classes:

• Polysorbates, including polysorbate 20 and polysorbate 80
• Poloxamers
• PEG-40 hydrogenated castor oil
• Polyoxyl 35 castor oil
• Macrogol 15 hydroxystearate
• Lecithin and phospholipid systems
• Self-emulsifying drug-delivery systems
• Cyclodextrins
• Lipid excipients and medium-chain triglycerides

Substitution depends on drug chemistry, route of administration, target dose, required surfactant concentration, oxidative stability, toxicity profile, and manufacturing process.

The main technical constraints are:

1. Batch-to-batch variation in ethoxylation and fatty-acid composition.
2. Oxidative degradation during storage.
3. Potential interaction with preservatives and active ingredients.
4. Taste and gastrointestinal effects in oral products.
5. Limited interchangeability across suppliers.
6. Higher qualification requirements for sterile or parenteral products.
7. Pressure to reduce excipient complexity in formulations.

The material can also lose share where developers choose newer lipid systems, cyclodextrins, amorphous solid dispersions, nanocrystals, or drug-device delivery technologies.

Which companies supply polyoxyl 60 hydrogenated castor oil?

Commercial supply is concentrated among established specialty-ingredient manufacturers and regional pharmaceutical-excipient distributors.

Supplier or brand family	Market position
BASF, Kolliphor RH 60	Global pharmaceutical excipient supplier with formulation and regulatory support
Nikko Chemicals, NIKKOL HCO-60-related grades	Japanese specialty surfactant supplier with pharmaceutical and cosmetic exposure
Regional excipient manufacturers	Often compete on price, local availability, and custom packaging
Pharmaceutical ingredient distributors	Provide inventory, qualification support, and regional logistics

Product names must be checked carefully. Similar names can refer to different degrees of ethoxylation, different purity grades, or different compendial identities. A customer qualifying “hydrogenated castor oil” without defining the exact grade, specification, site, and change-control obligations faces substitution risk.

Supplier competition is based on more than price. The decisive factors are often:

• Regulatory documentation
• Drug Master File or equivalent support
• GMP status
• Lot-to-lot consistency
• Global manufacturing footprint
• Change-notification procedures
• Residual solvent and elemental impurity controls
• Availability of samples and technical support
• Ability to support clinical-to-commercial scale-up

What is the financial trajectory for polyoxyl 60 hydrogenated castor oil?

The financial trajectory is likely to be gradual rather than explosive. Revenue growth should track pharmaceutical excipient demand, formulation outsourcing, and the number of poorly soluble products entering development.

Period	Expected commercial pattern
Near term	Stable demand from existing oral, topical, and specialty formulations
Medium term	Incremental growth from solubility-enhancement programs and reformulations
Longer term	Mixed outlook as novel delivery systems compete with conventional surfactants

The product has several characteristics that support margin preservation:

• Qualification creates switching costs.
• Pharmaceutical customers value documentation and continuity.
• Volumes are small relative to commodity excipients.
• Formulation failure can cost more than a modest excipient price difference.
• Approved formulations may continue buying the same grade for many years.

Margin pressure can arise from regional competition, dual-sourcing programs, raw-material volatility, freight costs, and customers seeking lower-cost alternatives. Hydrogenated castor oil and ethylene oxide derivatives are exposed to changes in oleochemical feedstock and petrochemical-linked input costs.

Public-company financial analysis should therefore focus on the supplier’s broader excipient business. Relevant indicators include pharmaceutical-excipient sales, specialty-ingredients operating margins, plant utilization, new customer qualification, price pass-through, and geographic expansion. Product-level revenue, EBITDA, and market share are generally not disclosed.

What regulatory status applies to polyoxyl 60 hydrogenated castor oil?

Polyoxyl 60 hydrogenated castor oil is an excipient, not an independently approved active pharmaceutical ingredient. FDA does not approve it as a drug. Its acceptability is assessed within the context of a specific finished product, route, concentration, dosage form, and manufacturing process.

FDA status and Inactive Ingredient Database

The FDA Inactive Ingredient Database is the principal public reference for prior U.S. use. A listing can support an applicant’s excipient justification, but it does not eliminate the need to establish quality, safety, compatibility, and suitability for the proposed product.[1]

The relevant regulatory questions include:

• Is the exact chemical identity represented?
• Is the proposed route of administration covered?
• Is the proposed maximum potency or concentration within prior precedent?
• Does the dosage form match?
• Is the supplier and manufacturing site controlled?
• Are impurity and degradation specifications appropriate?

European and international status

In Europe, excipient acceptance is evaluated through the medicinal-product authorization process and applicable European Pharmacopoeia requirements. The European Medicines Agency has issued general guidance addressing excipient quality and pharmaceutical development, while national and European pharmacopoeial standards may apply depending on the material and grade.[2][3]

Japanese and other Asian markets apply their own pharmacopoeial and regulatory requirements. Global developers must avoid assuming that an FDA precedent automatically transfers to the European Union, Japan, China, or other jurisdictions.

What patents protect polyoxyl 60 hydrogenated castor oil?

The base excipient is an established chemical class with limited prospects for broad, enforceable composition-of-matter exclusivity. The principal IP risk usually lies in supplier-specific manufacturing, purification, grade specifications, formulations, and uses rather than ownership of the generic excipient concept.

IP category	Relevance
Composition-of-matter patents	Generally weak for an established PEG-hydrogenated castor oil class
Manufacturing patents	Can protect reaction conditions, purification, impurity reduction, and consistency
Grade or specification patents	May protect defined composition ranges or performance characteristics
Formulation patents	Can cover a drug product containing the excipient
Method-of-use patents	May cover solubilization, delivery, stability, or treatment applications
Trade secrets	Important for process control, catalyst systems, purification, and analytical methods

There is no Orange Book listing for polyoxyl 60 hydrogenated castor oil itself because it is not an approved active drug product. Orange Book patents attach to approved drug products, not to the excipient as a standalone commercial ingredient.[4]

Paragraph IV litigation is therefore generally not directed at the excipient. A generic applicant may challenge patents covering a finished drug formulation that uses polyoxyl 60 hydrogenated castor oil, but that challenge concerns the drug product’s listed patents, not ownership of the excipient.

What patent litigation and generic-entry risks affect the market?

The direct generic-entry risk for the excipient is low. The material is not protected by the exclusivity framework applied to an approved active ingredient, and multiple suppliers can potentially produce comparable grades.

The important risks occur at the formulation level:

• A branded drug may have a formulation patent covering the surfactant system.
• A method-of-use patent may cover administration of a solubilized formulation.
• A manufacturing patent may restrict a specific sterile or low-impurity process.
• A supplier agreement may limit access to a proprietary grade or technical package.
• A product-specific patent may delay generic substitution even when the excipient itself is unprotected.

Generic applicants can usually seek non-infringing alternatives, design around a formulation claim, or use a different surfactant. The commercial challenge is proving equivalent performance, stability, bioavailability, and manufacturability.

How strong is the patent estate for polyoxyl 60 hydrogenated castor oil?

The standalone patent estate is likely weak to moderate, depending on the specific supplier grade and manufacturing process. The commercial moat is stronger than the basic patent moat.

Protection mechanism	Relative strength
Broad patent on the base excipient	Low
Supplier manufacturing know-how	Moderate to high
Regulatory documentation	Moderate
Customer qualification history	High
Formulation-specific patents	Moderate to high
Trademark and brand recognition	Moderate
Distribution and regional inventory	Moderate

A competitor can often manufacture a chemically similar surfactant, but commercial substitution can still take months or years because the pharmaceutical customer must complete vendor qualification, analytical comparability, stability testing, and regulatory assessment.

What manufacturing and supply-chain barriers exist?

Manufacturing requires controlled ethoxylation of hydrogenated castor oil, followed by purification, finishing, analytical testing, and pharmaceutical-grade packaging. The critical quality attributes include molecular-weight distribution, degree of ethoxylation, free polyethylene glycol, residual reactants, water content, acid value, hydroxyl value, peroxide value, and microbial quality.

Supply-chain exposure is concentrated in:

• Hydrogenated castor oil feedstock
• Ethylene oxide availability
• Specialized reaction capacity
• Pharmaceutical-grade purification
• Energy and transportation costs
• Regional regulatory documentation
• Single-site or single-supplier qualification

Customers may dual-source the excipient, but technical equivalence is not automatic. A change in supplier can alter particle size, melting behavior, viscosity, solubilization capacity, or impurity levels. This creates a meaningful operational barrier even where no blocking patent exists.

How does polyoxyl 60 hydrogenated castor oil compare with PEG-40 hydrogenated castor oil and polysorbate 80?

Attribute	Polyoxyl 60 hydrogenated castor oil	PEG-40 hydrogenated castor oil	Polysorbate 80
Core role	Solubilizer and emulsifier	Solubilizer and emulsifier	Emulsifier and wetting agent
Chemical profile	More highly ethoxylated hydrogenated castor-oil derivative	Lower nominal ethoxylation grade	Sorbitan ester with polyoxyethylene chains
Typical use	Oral, topical, specialty systems	Oral, topical, cosmetics, selected pharmaceutical uses	Broad pharmaceutical and biologic formulation use
Main concern	Grade variability and oxidation	Route-specific tolerability and specification	Peroxides, degradation products, protein interaction
Substitution	Requires formulation testing	Often considered as an alternative	Not directly interchangeable

Polyoxyl 60 hydrogenated castor oil can be attractive where a formulation requires a particular hydrophilic-lipophilic balance or viscosity profile. Polysorbate 80 has broader recognition in biologics and injectable formulations, but its degradation and peroxide profile can create separate development concerns.

What is the geographic coverage of the market?

Demand is global, but supply and regulatory acceptance are regionally segmented.

• North America: mature pharmaceutical excipient market with strong emphasis on FDA documentation and supply continuity.
• Europe: high demand for functional excipients, strong pharmacopoeial and quality expectations.
• Japan: established specialty-chemical suppliers and detailed excipient standards.
• China: growing domestic pharmaceutical manufacturing base and expanding local excipient capacity.
• India: strong generic-drug and contract-manufacturing demand, with price-sensitive procurement.
• Latin America and Southeast Asia: smaller direct markets, often served through distributors.

Asia is likely to remain important for volume growth because of generic-drug production, contract development, and expanding pharmaceutical manufacturing. North America and Europe remain important for high-value formulation work and regulated commercial products.

Key Takeaways

• Polyoxyl 60 hydrogenated castor oil is a niche pharmaceutical surfactant used mainly for solubilization, emulsification, and wetting.
• Standalone market revenue is not publicly disclosed; suppliers report it within broader excipient or specialty-ingredient categories.
• Financial growth should be gradual and linked to poorly soluble drugs, oral liquids, topical products, and formulation outsourcing.
• The excipient itself has limited standalone patent strength.
• Manufacturing know-how, regulatory documentation, customer qualification, and supply continuity create the main commercial barriers.
• FDA Orange Book listings and Paragraph IV litigation do not apply to the excipient as a standalone product.
• Finished drug products containing the excipient can still be protected by formulation, method-of-use, or manufacturing patents.
• Supplier substitution is technically possible but can require extensive comparability and stability work.
• BASF and Nikko Chemicals are among the recognized commercial sources associated with relevant hydrogenated castor-oil surfactant grades.
• No defensible public standalone revenue forecast exists without proprietary supplier data.

FAQs About Polyoxyl 60 Hydrogenated Castor Oil

Is polyoxyl 60 hydrogenated castor oil the same as Cremophor EL?

No. Cremophor EL is commonly associated with polyoxyl 35 castor oil, while polyoxyl 60 hydrogenated castor oil is a hydrogenated castor-oil derivative with a different composition and performance profile.

Can polyoxyl 60 hydrogenated castor oil be used in injectable drugs?

It may be considered for selected parenteral formulations, but oral or topical grade status does not establish injectable suitability. Sterility, endotoxin, impurity, oxidation, and route-specific safety requirements must be addressed in the finished product dossier.

Does polyoxyl 60 hydrogenated castor oil have a drug patent expiration date?

No standalone drug patent expiration date applies to the excipient. Any relevant patent date would relate to a supplier process, proprietary grade, or finished pharmaceutical formulation.

Is polyoxyl 60 hydrogenated castor oil listed in the FDA Inactive Ingredient Database?

The FDA Inactive Ingredient Database must be searched by the applicable chemical name, synonym, route, dosage form, and concentration. Database precedent is product-specific and does not constitute general approval for every use.[1]

What is the main investment risk in the polyoxyl 60 hydrogenated castor oil market?

The primary risk is limited product-level financial transparency. Investors typically obtain exposure through diversified specialty-chemical or pharmaceutical-excipient suppliers, where the product’s revenue and margin contribution are not separately reported.

References

1. U.S. Food and Drug Administration. (n.d.). Inactive Ingredient Database. https://www.fda.gov/drugs/drug-approvals-and-databases/inactive-ingredients-database-download
2. European Medicines Agency. (2016). Guideline on the sterilisation of the medicinal product, active substance, excipient and primary container. https://www.ema.europa.eu/
3. European Directorate for the Quality of Medicines & HealthCare. (2023). European Pharmacopoeia. Council of Europe.
4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files
5. BASF. (n.d.). Kolliphor pharmaceutical excipients. https://pharma.basf.com/
6. Nikko Chemicals Co., Ltd. (n.d.). Pharmaceutical and cosmetic surfactants. https://www.nikkol.co.jp/